We are focused on the rapid design and development of new medicines based on breakthroughs in cancer research.

Prelude’s approach is target class- and technology platform-agnostic, meaning we do not limit our selection of programs to a defined target class (e.g., kinases) or a technology platform (e.g., protein degradation). Instead, Prelude applies its deep expertise in cancer biology and medicinal chemistry to identify targetable intervention points in cancer signaling pathways amenable to small molecule-based therapies. Once an optimal target is identified, Prelude employs its internal discovery engine and extensive understanding of the current oncology treatment landscape to design and synthesize molecules with optimized properties. Prelude’s clinical development programs are focused on early proof of concept and efficient regulatory pathways that enable potentially transformative medicines to quickly reach cancer patients with high unmet medical need.  


Science Overview Grapic